Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 19 - Drugs for skeletal disorders
Patents for A61P 19 - Drugs for skeletal disorders (81,981)
04/2003
04/09/2003CN1408401A Cherry extract and its extracting method
04/09/2003CN1408394A Method for preparing toxic removing medicine dilingdan
04/09/2003CN1408386A Bone arthralgia syndrome medicine and its preparing method
04/09/2003CN1408376A Oral composition for increasing bone density, and its preparing method and use
04/09/2003CN1105114C Sulfonyl divalent aryl alpha-hydroxy-iso-hydroximic acid compounds
04/09/2003CN1105101C Beta-sultonamido hydroxamic acids as matrix metalloproteinase and TACE inhibitors
04/08/2003WO2002034715A1 Benzamidine derivatives comprising a sulfate group serving as ltb4 antagonists
04/08/2003US6545182 Methods and compositions for modulating alpha adrenergic receptor activity
04/08/2003US6545158 Such as N-(3,5-dichloropyridin-4-yl)-2-(1-(4-fluorobenzyl)-5-hydroxyindol-3-yl)-2 -oxoacetamide; for treatment of eosinophil-related disorders and chronic obstructive pulmonary disease
04/08/2003US6545137 Autoimmune diseases; antiinflammatory agents; viricides; antidiabetic agents; binding to low density lipoproteins
04/08/2003US6545050 Aryl sulphonamide amino acid esters and analogues
04/08/2003US6545038 Heterocyclic metalloprotease inhibitors
04/08/2003US6545030 1-heterocycle substituted diarylamines
04/08/2003US6545025 Antiinflammatroy agents; antiallergens
04/08/2003US6545023 For treating rheumatoid arthritis; for examle, 1-(4-(4-fluorophenyl)piperidin-1-yl),3-(2-methoxy-4 -chlorobenzylaminocarbonyl),3-isopropyl-cyclopentane
04/08/2003US6545018 Oxamic acids and derivatives as thyroid receptor ligands
04/08/2003US6545013 2,7-naphthyridine derivatives
04/08/2003US6545005 Mediators of hedgehog signaling pathways, compositions and uses related thereto
04/08/2003US6545004 Treating cellular proliferative diseases and disorders associated with KSP kinesin activity.
04/08/2003US6545003 Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
04/08/2003US6544991 Compositions and methods for treating bacterial infections
04/08/2003US6544988 Tyrosine kinase inhibitors
04/08/2003US6544984 2,3,4,5-tetrahydro-1H-(1,4)benzodiazepine-3-hydroxamic acids
04/08/2003US6544981 Anticoagulants, cardiovascular disorders
04/08/2003US6544969 26,27-homologated-20-epi-2-alkyl-19-nor-vitamin D compounds
04/08/2003US6544561 Neutral to mildly alkaline; preventing and/or treating certain inflammatory diseases and/or degenerative diseases and/or certain viral diseases in a mammal
04/08/2003US6544556 Prevents gastrointestinal side effects
04/08/2003US6544541 Devices and compounds for treating arterial restenosis
04/08/2003CA2050300C Tnf-inhibiting proteins and the preparation thereof
04/07/2003WO2002032866A1 (4-acylaminopiperidin-1-yl) acetamides as neurokinin antagonists
04/03/2003WO2003027287A1 Kidney-specific urate transporter and gene thereof
04/03/2003WO2003027285A1 Dna sequences for human angiogenesis genes
04/03/2003WO2003027284A1 Bone metablic disease markers and utilization thereof
04/03/2003WO2003027282A1 Adamts-15, -16, -17, -18 and -19
04/03/2003WO2003027263A2 Proteins associated with cell growth, differentiation, and death
04/03/2003WO2003027248A2 Antibody inhibitors of gdf-8 and uses thereof
04/03/2003WO2003027234A2 Small organic molecule regulators of cell proliferation
04/03/2003WO2003027232A2 Method for producing biologically active products
04/03/2003WO2003027154A1 Polymers with structure-defined functions
04/03/2003WO2003027151A1 Recombinant anti-osteopontin antibody and use thereof
04/03/2003WO2003027115A1 Substituted 2-pyrimidinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyrimidinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives for neurodegenerative disorders
04/03/2003WO2003027114A1 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for treatment of obesity
04/03/2003WO2003027111A1 Chemical compounds
04/03/2003WO2003027108A1 Heterocyclic derivatives and their use as hypoglycaemic and hypolipidemic agents
04/03/2003WO2003027102A1 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003027077A1 Water-soluble phenylpyridazine derivatives and drugs containing the same
04/03/2003WO2003027075A2 Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
04/03/2003WO2003027069A1 Preparation and use of pyrrole derivatives for treating obesity
04/03/2003WO2003027065A1 3-desoxy-vitamin d3 analog esters
04/03/2003WO2003026714A1 Porous ceramic composite bone grafts
04/03/2003WO2003026692A2 Treatment of chronic joint inflammation using an antibody against the cd3 antigen complex
04/03/2003WO2003026689A1 Autologous growth factor cocktail composition, method of production and use
04/03/2003WO2003026677A1 Pharmaceutical composition comprising chito-oligomers
04/03/2003WO2003026673A1 Modulation of vitamin storage
04/03/2003WO2003026663A1 Process for making substituted pyrazoles
04/03/2003WO2003026662A1 Solid-state forms of n-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl)pyrazole
04/03/2003WO2003026660A1 An enantiomerically pure diarylmethylpiperazine and methods of using same
04/03/2003WO2003026650A1 3-(heteroarylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
04/03/2003WO2003026579A2 Combination therapies for immune mediated diseases
04/03/2003WO2003026568A2 Androstanes as androgen receptor modulators
04/03/2003WO2003026408A1 Model animal with overexpression of regucalcin
04/03/2003WO2003002531A3 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2003002530A3 Pyrrolidines as dipeptidyl peptidase inhibitors
04/03/2003WO2002102313A3 Pyrimidine inhibitors of phosphodiesterase (pde) 7
04/03/2003WO2002100332A3 Isoxazoline compounds having mif antagonist activity
04/03/2003WO2002092563A3 Protease inhibitors
04/03/2003WO2002092016A3 Therapeutic use of rank antagonists
04/03/2003WO2002086078A3 Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
04/03/2003WO2002074738A3 Spiro-cyclic beta-amino acid derivatives as inhibitors of matrix metalloproteinases and tnf-alpha converting enzyme (tage)
04/03/2003WO2002074230A3 A dna molecule encoding a variant paraoxonase and uses thereof
04/03/2003WO2002073213A3 Assay
04/03/2003WO2002070559A3 Nuclear hormone receptor ligand binding domains
04/03/2003WO2002062352A3 Devices and methods for management of bone density
04/03/2003WO2002039954A3 Novel compounds
04/03/2003WO2002024943A9 Method of identifying osteoregenerative agents using differential gene expression
04/03/2003WO2002024909A9 Receptor nucleic acids and polypeptides
04/03/2003WO2002022166A9 Tweak receptor agonists as anti-angiogenic agents
04/03/2003WO2002014369A9 Human kininogen d5 domain polypeptides and their use
04/03/2003WO2002000860A3 Novel proteases
04/03/2003US20030065214 Novel hydrate forms of alendronate sodium, processes for manufacture thereof, and pharmaceutical compositions thereof
04/03/2003US20030065174 Antiinflammatory agents; analgesics
04/03/2003US20030065018 Substituted 4H-chromenes and analogs as activators of caspases and inducers of apoptosis and the use thereof
04/03/2003US20030065017 Pharmaceutical compositions, kits and methods comprising combinations of estrogen agonists / antagonists, estrogens and progestins
04/03/2003US20030065012 Estrogen receptor modulators
04/03/2003US20030065008 Hormone replacement therapy; side effect reduction
04/03/2003US20030065007 Analgesics; psychological disorders; antidepressants
04/03/2003US20030065004 Androgen receptor modulators and methods for use thereof
04/03/2003US20030064996 Anticarcinogenic agents, antiinflammatory agents, anticholesterol agents, antidiabetic agents
04/03/2003US20030064987 Immunology moderators; interleukin antagonist; anticancer agents
04/03/2003US20030064966 Bone disorders; osteoporosis
04/03/2003US20030064964 Osteoporosis; increase bone density
04/03/2003US20030064958 Pharmaceutical compositions and methods relating to fucans
04/03/2003US20030064952 Nucleic acids, polypeptides, compositions, and methods for modulating apoptosis
04/03/2003US20030064938 Cardiovascular disorders; menstraution disorders; anticancer agents
04/03/2003US20030064928 Therapeutic preparations for inhalation
04/03/2003US20030064919 Novel polypeptides and polynucleotides encoding same
04/03/2003US20030064493 Methods and means for modulating PGE synthase activity
04/03/2003US20030064430 Novel steroid-activated nuclear receptors and uses therefor
04/03/2003US20030064426 Expression vector for use in the treatment of cancer and age-related defects
04/03/2003US20030064410 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids
1 ... 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 ... 820